JP Morgan Maintains Underweight on Myriad Genetics, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Rachel Vatnsdal has maintained an Underweight rating on Myriad Genetics (NASDAQ:MYGN) and lowered the price target from $17 to $14.
November 07, 2023 | 8:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
JP Morgan has maintained an Underweight rating on Myriad Genetics and lowered the price target from $17 to $14.
The lowered price target by JP Morgan indicates a bearish outlook for Myriad Genetics. This could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100